Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses
February 7, 2020 9:14 AM EST
Jefferies analyst Brandon Couillard lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $19.00 (from $23.00) while maintaining a Hold rating.
The analyst commented, "We expect MYGN to open sharply lower (down >20% after-hours) after another 2Q miss, ~50% cut to '20 EPS guide & abrupt CEO... More
February 6, 2020 4:14 PM EST
Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Companys Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.
As we position Myriad for its next phase of growth and... More
